Edesa Biotech (EDSA)
Develops clinical candidates for inflammatory and immune-related diseases.
Something off on this page? Send us feedback.
Develops paridiprubart, EB06, and EB01 for respiratory, dermatologic, and immune-related conditions. The Canadian clinical-stage biopharmaceutical company has no approved product portfolio and reached Nasdaq through a reverse acquisition.
Develops clinical-stage candidates for inflammatory and immune-related diseases. Its programs include paridiprubart (EB05), an ARDS monoclonal-antibody program; EB06 for a planned Phase 2 vitiligo study; and EB01 (daniluromer), which completed a Phase 2b study in allergic contact dermatitis. No approved product portfolio is represented in its current materials.
The Canadian company operates through Ontario and California subsidiaries and reached Nasdaq through a 2019 reverse acquisition. Pardeep Nijhawan has led the company since that transaction after leading the Ontario operating business.
Development depends on additional financing, strategic activity, grants, and Canadian Strategic Innovation Fund support, whose later agreement includes conditions and partial-repayment provisions.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.3M · Total debt $0 · Total assets $12.7M · Shareholders' equity $8.8M
- Revenue
- $0
- Operating income
- −$5.5M
- Net income
- −$5.4M
No dividends on record.
| Institutions27 holders · as of Mar 31, 2026 | 27.42% | 2.64M shares | |
| Insiders10 holders · as of Sep 1, 2026 | 20.44% | 1.97M shares | |
| Strategic holders1 holder · as of Jun 18, 2026 | 5.40% | 520.7K shares | |
| Otherremainder | 46.74% | 4.51M shares |
9.64M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Pardeep NijhawanInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 13.50% | 1.30M | Form 4filed Sep 1, 2026 ↗ |
Velan Capital Investment Management LPInstitution | 8.58% | 827,500 | 13Fas of Mar 31, 2026 |
Rubric Capital Management LPInstitution | 7.13% | 687,500 | 13Fas of Mar 31, 2026 |
Sirenia Capital Management LPInstitution | 6.22% | 600,000 | 13Gfiled May 15, 2026 ↗ |
Perceptive Advisors LLCInstitution | 5.84% | 563,239 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 26, 2026 | Michael J. Brooks | officer: President | +2,000 | $1.57 |
| Mar 5, 2026 | Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | +10,000 | $3.90 |
| Mar 4, 2026 | Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | +10,000 | $4.26 |
| Mar 3, 2026 | Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | +10,000 | $3.63 |
| Mar 2, 2026 | Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | +3,000 | $2.09 |
